Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hitoshi Terui has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between Psoriasis Area and Severity Index Score and atherosclerotic risk in psoriasis patients using the Hisayama Score: a single-center retrospective study

    by Airi Kobayashi, Hitoshi Terui, Ryoko Shimada-Omori, Toshiki Okazaki, Mana Sekine, Miyu Yano, Takehiro Takahashi, Yoshihide Asano

    Psoriasis is a chronic immune-mediated skin disorder causing systemic inflammation, which significantly increases the risk of cardiovascular disease (CVD). In Japan, the Hisayama Score was recently introduced as a comprehensive tool to assess coronary artery disease and stroke risk. This retrospective study represents the first investigation applying the Hisayama Score to psoriasis patients to determine the association between the Psoriasis Area and Severity Index (PASI) and cardiovascular risk. We analyzed data from 119 patients aged 40-79 visiting Tohoku University Hospital between 2010 and 2022. After excluding 48 patients with pre-existing comorbidities like diabetes and chronic kidney disease, 71 participants remained. Patients were stratified into low, moderate, and high-risk groups based on blood pressure, lipid profiles, and smoking history. Results showed that higher PASI scores were significantly associated with increased cardiovascular risk (p = 0.003). Notably, male patients with PASI scores exceeding 10 were frequently categorized into moderate or high-risk groups (p = 0.049). Additionally, systolic blood pressure was identified as an independent predictor. These findings suggest that psoriasis severity correlates with elevated cardiovascular risk, validating the Hisayama Score's utility in this population and highlighting the critical need for dermatologists to implement proactive, interdisciplinary risk management strategies.

  • Open Access

    Dermatofibroma Associated with Lymphoid Follicles Harboring Germinal Center: A Case Report

    by Masatoshi Deguchi, Moyuka Wada-Irimada, Hitoshi Terui, Takuya Takahashi, Yoshihide Asano

    Introduction: Dermatofibromas (DFs) are common, benign firm dermal nodules. It is well known that their onsets often follow minor injuries, including insect bites or arthropod assaults on-site. The frequency of DF cases associated with lymphoid follicles (LF) harboring germinal center (GC) amounts to around 1∼4%. The pathogenesis of this peculiar association is currently unknown, leaving a challenging topic for interpretation. Case Presentation: We present a case of a 55-year-old, otherwise healthy woman with a slightly erythematous flat nodule on the right side of her neck. It had occurred 3 months after a mosquito bite on the same site, and the lesion was tender. The nodule was eradicated completely from the right side of her neck as excisional biopsy after the treatment of secondary infection. Histopathological specimen revealed a fibrocollagenous type of DF with well-organized multiple B-cell secondary LFs. Their GCs indicated harboring bcl-6-positive, CXCR5-positive follicular helper T cells in the network of follicular dendritic cells. In addition, they were surrounded by CD163-positive-DC-SIGN (CD209)-positive macrophages expressing Toll-like receptor (TLR) 4. We diagnosed the lesion as DF associated with LF harboring GC, presumably driven by the Th27/Th2 microenvironment. Conclusion: Given that GC-associating LF in the present case is presumed to manifest Th27/Th2 microenvironment formation, the implication is that it plays a role in humoral immunity against extracellular pathogens. When miscellaneous pathogens bearing fucose-containing carbohydrate antigens happened to invade the dermis through minor injuries, DC-SIGN, a pattern recognition receptor, and TLR4 on macrophages may have modulated Th differentiation into Th27/Th2 to generate follicular helper T cells and GC to induce humoral immunity. Accumulation of reports is required to check the validity of this speculation.

  • Coronary Artery Disease Assessment in Psoriasis Patients Well‐Controlled Under Systemic Anti‐Inflammatory Treatments—A Real‐World Observational Study From a Single Center

    by Toshiki Okazaki, Hitoshi Terui, Takehiro Takahashi, Airi Kobayashi, Mana Sekine, Ryoko Shimada‐Omori, Kensuke Nishimiya, Hidenobu Takagi, Hideki Ota, Yoshihide Asano

    Atherosclerosis is now considered to reflect systemic inflammation involving the elevation of multiple proinflammatory cytokines, sharing common underlying pathophysiological mechanisms with psoriasis. There has been increasing interest in whether anti‐inflammatory treatment of psoriasis can prevent or halt the progression of atherosclerosis. Here, we conducted a cross‐sectional observational clinical study in psoriasis patients with at least one traditional cardiovascular risk factor, such as diabetes, hypertension, or dyslipidemia, and who were being treated with systemic anti‐inflammatory drugs. To assess CAD risk, we performed coronary computed tomography angiography (CCTA). We assessed 27 psoriasis patients (14 males/13 females), whose median PASI score was 0 [range, 0–2.3] at the time of CCTA. They had sustained well‐controlled psoriasis for a median of 44 months [range, 1–144]. Coronary plaques of varying degrees were detected in 20 patients (74%) by CCTA. Four patients were diagnosed with silent myocardial ischemia (SMI) by invasive coronary angiography (CAG), revealing severe coronary stenosis in major arteries. The severity of coronary plaque burden was significantly associated with male sex, hypertension, and carotid ultrasound abnormalities. Furthermore, notably, we detected a significant positive correlation between the duration of biologic treatment and calcified plaque burden among patients treated with biologic agents for over 6 months. Our study highlights the importance of tight disease control and screening for CAD even in well‐controlled psoriasis patients. Further accumulation of studies may lead to better management of CAD risks in this population.

  • A case of systemic sclerosis accompanying psoriasis successfully treated with brodalumab

    by Yuichiro Segawa, Takehiro Takahashi, Yoshiko Mikami, Takuya Takahashi, Hitoshi Terui, Tetsuya Ikawa, Yoshihide Asano

  • Open Access

    Successful Treatment of Unresectable BRCA1 L63*-Mutated Basal Cell Carcinoma Invading the Parietal Bone with Cisplatin and Fluorouracil: A Case Report

    by Saaya Yoshida-Akai, Taku Fujimura, Ryo Amagai, Yumi Kambayashi, Akira Hashimoto, Hitoshi Terui, Kenta Oka, Manami Watanabe-Takahashi, Emi Yamazaki, Kota Ohuchi, et al.

    Introduction: Basal cell carcinoma (BCC) is a common skin cancer that rarely metastasizes but can deeply infiltrate local tissues. The small number of unresectable BCC cases makes it difficult to conduct clinical trials, resulting in delays in the development of effective drugs for BCC. Cancer gene panel testing has led to an increasing number of new treatment proposals for patients with solid tumors for whom no standard treatment is available. Case Presentation: We described a case of unresectable BRCA1 L63*-mutated BCC invading the parietal bone, which was successfully treated with cisplatin and fluorouracil. Conclusion: Our present case suggests that comprehensive mutation analysis by gene panel testing is important in advanced BCC because genes other than those involved in the hedgehog signaling pathway can be driver genes.

  • Serum levels of AGGF1: Potential association with cutaneous and cardiopulmonary involvements in systemic sclerosis

    by Takuya Takahashi, Takehiro Takahashi, Tetsuya Ikawa, Hitoshi Terui, Toshiya Takahashi, Yuichiro Segawa, Hayakazu Sumida, Ayumi Yoshizaki, Shinichi Sato, Yoshihide Asano

    Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, aberrant immune activation, and extensive tissue fibrosis of the skin and internal organs. Because of the complicated nature of its pathogenesis, the underlying mechanisms of SSc remain incompletely understood. Angiogenic factor with a G‐patch domain and a Forkhead‐associated domain 1 (AGGF1) is a critical factor in angiogenesis expressed on vascular endothelial cells, associated with inflammatory and fibrotic responses. To elucidate the possible implication of AGGF1 in SSc pathogenesis, we investigated the association between serum AGGF1 levels and clinical manifestations in SSc patients. We conducted a cross‐sectional analysis of AGGF1 levels in sera from 60 SSc patients and 19 healthy controls with enzyme‐linked immunosorbent assay. Serum AGGF1 levels in SSc patients were significantly higher than those in healthy individuals. In particular, diffuse cutaneous SSc patients with shorter disease duration had higher levels compared to those with longer disease duration and limited cutaneous SSc patients. Patients with higher serum AGGF1 levels had a higher incidence of digital ulcers, higher modified Rodnan Skin Scores (mRSS), elevated serum Krebs von den Lungen‐6 (KL‐6) levels, C‐reactive protein levels, and right ventricular systolic pressures (RVSP) on the echocardiogram, whereas they had reduced percentage of vital capacity (%VC) and percentage of diffusing capacity of the lungs for carbon monoxide (%DLCO) in pulmonary functional tests. In line, serum AGGF1 levels were significantly correlated with mRSS, serum KL‐6 and surfactant protein D levels, RVSP, and %DLCO. These results uncovered notable correlations between serum AGGF1 levels and key cutaneous and vascular involvements in SSc, suggesting potential roles of AGGF1 in SSc pathogenesis.


  • A case of lymphangiectatic variant of giant pilomatricoma with bullous appearance: evaluation through magnetic resonance imaging

    by Airi Kobayashi, Hitoshi Terui, Toshiya Takahashi, Masato Mizuashi, Yoshihide Asano

  • Author reply to antibiotics in SAPHO syndrome

    by Hitoshi Terui, Yuichiro Segawa, Eika Otake, Ryoko Omori, Kenichiro Tsuchiyama, Katsuko Kikuchi, Kenshi Yamasaki, Setsuya Aiba, Yoshihide Asano

  • Targeting B cells for treatment of systemic sclerosis

    by Hitoshi Terui, Yuichiro Segawa, Yoshihide Asano

    Purpose of review: The pathogenesis of systemic sclerosis (SSc) has been linked to dysfunctional B cells as demonstrated in previous research. This review aims to show the evidence and ongoing clinical trials of B cell-targeted therapy and overview the various aspects of B cell involvement in SSc. Recent findings: We provide an overview of the current understanding and therapeutic strategies targeting B cells in SSc patients. Several molecular targets of B cells have been identified for treating SSc, including CD20, CD19, B-cell activating factor (BAFF), and proteasome. Summary: Many clinical trials have demonstrated that B cells play a critical role in the pathogenesis of SSc and may be a potential therapeutic target to improve disease symptoms. Although large-scale clinical studies are needed, various B cell-targeted therapies have the potential to address the unmet needs of SSc patients.


  • Open Access

    Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer

    by Mana Sekine, Hitoshi Terui, Taku Fujimura, Yoshihide Asano

    Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor. Since olaparib is a newly approved drug, there are few reports of skin disorders that may be triggered by olaparib administration. In this report, we present a case with an olaparib-induced drug eruption presenting multiple purpuras on the patient’s fingers and fingertips. The present case suggests that olaparib might induce purpura as nonallergic drug eruption.